Introduction
CD30 is a member of the tumor necrosis factor receptor family, which includes TNF-R1, TNF-R2, Fas-R, CD40, CD27 and TRAIL-R. 1 Increased expression of CD30 is observed on some neoplasms including Hodgkin's disease, anaplastic large cell lymphoma (ALCL), mediastinal B-cell lymphoma, embryonal carcinoma, seminoma and mesothelioma. [2] [3] [4] [5] [6] [7] In contrast, its expression in normal tissues is limited to activated Tcells, activated B-cells, select thymocytes, and some vascular beds. 3 This expression on neoplasmas versus its limited expression on normal tissues makes it a promising target for antibody-based therapy.
HeFi-1 is a murine IgG1, which recognizes the ligand-binding site on CD30. Anaplastic large cell lymphoma (ALCL) represents a heterogeneous group of aggressive nonHodgkin's lymphomas characterized by the strong expression of CD30 and a frequent involvement of the t(2;5) chromosomal translocation. 8 Despite responsiveness to chemotherapy, approximately one-third of the patients with ALCL die regardless of intensive chemotherapy. Thus, alternative clinical approaches need to be developed.
Anti-CD30 antibody-based immunotherapy has been investigated in vitro and in vivo. [9] [10] [11] [12] CD30 mediated signal transduction is capable of promoting cell proliferation and cell survival as well as antiproliferative effects and cell death depending on cell type and costimulatory effects. 13 CD30 activation was reported to induce cell growth inhibition and apoptosis with some but not all ALCL cells. 9, 10, 14 In particular, the treatment of ALCLderived cell lines, karpas299 and Michel, with two antibodies (M44, HeFi-1), that recognize the ligand-binding site of CD30 led to a significant reduction of cell viability. 10 only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013 . bloodjournal.hematologylibrary.org From bearing extensive metastases of karpas299 were significantly enhanced by anti-CD30 treatment. 12 In the present study, we investigated the efficacy of HeFi-1 in a murine model of human ALCL. We were particularly interested in the mechanism underlying the inhibition of the tumor growth mediated by HeFi-1 on ALCL. The anti-CD30 monoclonal antibody, HeFi- 
Materials and Methods

Monoclonal antibodies
HeFi-1, which is a mouse IgG1 directed toward the ligand-binding site on CD30, was provided by the Biological Response Modifiers Program, National Cancer InstituteFrederick Cancer Research Center. The humanized anti-Tac antibody (daclizumab), which recognizes CD25 (IL-2Rα), was obtained from Hoffmann-La Roche (Nutley, NJ).
Murine anti-Tac (MAT), which recognizes the same epitope as daclizumab does, was produced as described previously. 15 All of the mice used in this study were 8-10 week-old, and the ages of the mice in the different groups in the same experiment were matched. All animal experiments were performed in accordance with National Institutes of Health Animal Care and Use Committee guidelines.
Expression of CD30 and CD25 on karpas299 cell surfaces
The expression of CD30 and CD25 on karpas299 cell surfaces was analyzed by flow cytometry. Aliquots of 1x10 6 karpas299 cells were incubated with the primary antibody, HeFi-1 or MAT or isotype control antibodies (1 µg/100 µL) on ice for 30 min. The cells were washed and then stained with a FITC-labeled goat anti-mouse IgG antibody (SouthernBiotech). After washing, the cells were analyzed for the expression of CD30
and CD25 using a FACScan flow cytometry (Becton Dickinson, San Jose, CA).
Immunoreactivity of radiolabeled HeFi-1 and daclizumab
Conjugation of HeFi-1 and daclizumab to CHX-A" was performed as previously described. 18 HeFi-1-CHX-A", daclizumab-CHX-A" and B3-CHX-A" were labeled with 111 In at specific activities of 74-111 kBq/μg as described previously. 19 Modfit software (Verity, Topsham, ME).
Therapy study
For the evaluation of therapeutic efficacy of the anti-CD30 antibody, HeFi-1, and the anti-CD25 antibody, daclizumab, groups of karpas299 lymphoma bearing SCID/NOD wild type mice were injected with 100 μg of HeFi-1, daclizumab, or 200 μL of PBS i.v.
only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From weekly for 4 weeks. To define the mechanism of action of the antibodies, the second therapeutic study was performed in karpas299 bearing SCID/NOD wild type and SCID/NOD FcRγ -/-mice using the same dose schedule as that used in the first experiment. Throughout the experiment, the tumor progression was monitored by body weight and/or Kaplan Meier analysis of survival of the karpas299 bearing mice. We repeated the therapeutic study once using HeFi-1 and daclizumab at the same dose schedule and with the same tumor model in both SCID/NOD wild type and SCID/NOD FcRγ -/-mice.
Measurement of the ALCL lymphoma growth
The growth of the ALCL lymphoma was confirmed by pathologic examination 
Statistical analysis
The serum levels of sIL-2Rα and the body weight of the karpas299 lymphoma bearing mice were analyzed at different time points for the different treatment groups using the Student's t-test for unpaired data. Statistical significance of differences in survival of the mice in different groups was determined by the log-rank test using StatView program (Abacus Concepts Inc., Berkeley, CA).
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Results
Immunoreactivity of radiolabeled HeFi-1 and daclizumab
HeFi-1 and daclizumab target distinct receptors, CD30 and CD25, respectively, that are expressed on the karpas299 cell surfaces (Fig. 1A) . Both 111 In-HeFi-1 and 111 Indaclizumab bound to karpas299 cells specifically with a maximum binding of more than 90% of the added radiolabeled antibody (Fig.1B) .
Antiproliferation effect of HeFi-1
Karpas299 cells were treated with medium alone or with the antibodies at a concentration of 20 μg/mL for 48 hours. HeFi-1 inhibited the proliferation of the cells by 40% when compared with cells treated with medium alone or the isotype control, B3 antibody, whereas daclizumab did not inhibit the proliferation of the cells ( Fig.2A ).
HeFi-1 mediated cell cycle arrest
To examine which mechanism plays a major role in inhibiting the proliferation of karpas299 cells, the cells were treated with the antibodies for 48 hours and then apoptosis and cell cycle analyses were performed. HeFi-1 inhibited the cell growth mainly by causing cell cycle arrest at G1 phase (Fig. 2B) . In contrast, daclizumab did not show any affect on the cell cycle (Fig. 2B ).
ALCL Lymphoma model
SCID/NOD mice were used to establish this model because the mice lack functional B, T, and NK cells. After i.v. injection of 1x10 7 karpas299 cells, the animals began to die only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From around 4 weeks and all of the karpas299 bearing mice succumbed to the lymphoma within 2 months (Fig.3A) . Autopsy showed that numerous tumor nodules developed around the neck and head, as well as some in the peritoneal cavity and some of the mice developed tumors in eyes and cranium. Pathologic examination showed that there was widespread tissue distribution of the lymphoma including bone marrow, lymph nodes, brain, kidney, eye, as well as cranium. The body weight of the karpas299 lymphoma bearing mice decreased with disease progression (Fig.3B) . Although the serum levels of sIL-2Rα and β2μ were not detectable at an early stage of disease, these increased over time ( Fig. 3C ) and reached levels of 25,000-300,000 pm/mL and 1-10 ng/mL, respectively, immediately before death (Fig.3D ).
Therapeutic study with HeFi-1 and daclizumab
In the therapeutic study, HeFi-1 or daclizumab was injected i.v. weekly for 4 weeks at a dose of 100 μg. Therapeutic effects in SCID/NOD wild type mice bearing karpas299 lymphoma were demonstrated by their effects on the serum levels of sIL-2Rα (Fig.4A ), a surrogate tumor marker which was indicative of the tumor load of karpas299 lymphoma in the murine model and by the survival of the lymphoma bearing mice (Fig.4B ). When compared with the serum concentration of sIL-2Rα in the control group, on day 21 after therapy, there was a reduction of sIL-2Rα levels in the daclizumab treatment group, although it did not achieve statistical significance (Fig.4A ). In addition, there was a significant reduction of sIL-2Rα levels in the HeFi-1 treatment group (Fig.4A, p<0 .001).
Furthermore, there was a significant prolongation of the survival of the mice in the treatment groups receiving ether HeFi-1 or daclizumab when compared with that in the only.
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FcRγ expression is required for effective action of daclizumab, but not for that of
HeFi-1
Both HeFi-1 and daclizumab demonstrated therapeutic efficacy in the karpas299 lymphoma model, although HeFi-1 was more effective than daclizumab (Fig.4A & 4B) .
To define the mechanism of action of the antibodies, another therapeutic study was performed in the karpas299 bearing SCID/NOD wild type and SCID/NOD FcRγ -/-mice to determine whether Fc-dependent cellular cytotoxicity is involved in the mechanism of the tumor killing by HeFi-1 and daclizumab. The therapeutic efficacy of daclizumab in the lymphoma bearing SCID/NOD wild type mice was repeated. Daclizumab, given i.v.
weekly for 4 weeks at a dose of 100 μg, prolonged the survival of the karpas299 lymphoma bearing SCID/NOD wild type mice significantly as compared with the control group (Fig. 5A, p<0 .01). The mean survival duration of the control group was 26.2 days whereas it was prolonged to 34.4 days in the daclizumab group. However, the daclizumab, given at the same dose schedule as that in the karpas299 lymphoma bearing SCID/NOD wild type mice, did not show any therapeutic efficacy in SCID/NOD FcRγ -/-mice bearing the same quantity of the karpas299 cells. There were no statistical differences in the survival and the body weight of the mice observed between the daclizumab treatment group and the control group in SCID/NOD FcRγ -/-mice bearing karpas299 lymphoma (Fig. 5B & 6B) . In contrast, HeFi-1 showed therapeutic efficacy in only.
For (Fig. 5A & 5B) and the body weight ( Fig.6A & 6B) ). There were significant differences of the body weight between the HeFi-1 treatment group and the control group in both SCID/NOD wild type and SCID/NOD FcRγ -/-mice bearing karpas299 lymphoma (Fig.6A & 6B, For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From rituximab in the treatment of a CD20 expressing B-cell lymphoma in murine models. 28 Recently, they defined another common γ chain-dependent activating Fc receptor, FcγRIV to which murine IgG2a and IgG2b bound with intermediate affinity. 32 In contrast, murine IgG1 did not bind to this receptor. Human IgG1 preferentially bound to mouse FcγRIV, in addition to binding to mouse FcγRIII, accounting for its FcγR-dependent action in vivo. 32 We have demonstrated the requirement for FcγR expression in the action of the CD25 directed monoclonal antibodies daclizumab, murine anti-Tac and 7G7/B6, the CD52 directed monoclonal antibody CAMPATH-I and the CD2 directed monoclonal antibody MEDI -507, in a murine model of human adult T-cell leukemia. [29] [30] [31] In contrast, Clynes, Ravetch and coworkers demonstrated that the disruption of the gene that encodes the inhibitory FcRIIγB-Ig binding receptor substantially enhanced antitumor activity. 28 In contrast to these observations with other monoclonal antibodies, active Tian and coworkers also indicated that anti-tumor effects of unconjugated HeFi-1 involved apoptosis of the target ALCL cells. 12 However, Schneider and coworkers provide an alternative perspective. 14 They reported that the activation of CD30 did not only.
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